SEC Form 4 · accession 0000907654-26-000054
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Dambkowski
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 4:36 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 11, 2026 | S | 22,417 | $70.1343 | D | 51,326 | D | |
| Common StockF3 | Jun 12, 2026 | S | 12,583 | $70.109 | D | 38,743 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.